Semi-annual
Journal Content
Search
Search scope
Journal Center
Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.
Volume Arrangement
2024
https://doi.org/10.54517/urr.v5i1
DOI:
by
Swathi Madagam
Urin. Renal. Res.
2024
,
5(1);
135 Views
Abstract
Chronic kidney disease (CKD) affects 10%–13% of the global population, necessitating innovative treatments. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, shows promise by reducing glycated hemoglobin and benefiting kidney and cardiovascular health. By spotlighting renoprotective mechanisms like glucose control and anti-inflammatory effects, insights from trials such as EMPA-REG OUTCOME unveil decreased kidney disease progression, improved eGFR, and reduced albuminuria with empagliflozin. Safety profiles and comparisons: Evaluating safety profiles, potential adverse events, and comparisons with other SGLT2 inhibitors provides a nuanced perspective on the therapeutic potential of empagliflozin. The review emphasizes the importance of diverse CKD population studies, continuous safety monitoring, and exploring SGLT2 inhibitors in specific demographics. In summary, empagliflozin emerges as a versatile therapeutic option in the SGLT2 inhibitor class for CKD, reshaping disease management. Final thoughts: Ongoing research and vigilant monitoring are crucial for maximizing the potential of SGLT2 inhibitors, especially empagliflozin, to enhance patient well-being in CKD.
show more
Editor-in-Chief
Prof. Wei-Yen Hsu
National Chung Cheng University, Taiwan
News & Announcements
2023-08-28
New version of author guideline format
Author Guideline provides the new version of manuscript format guidence,which aims to provide layout formatting instructions for paper published on Journal of Urinary and Renal Research.
2022-08-10
EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer
Urinary extracellular vesicles (uEVs) secreted from bladder cancer contain cancer-specific proteins that are potential diagnostic biomarkers. Biomarker candidates, selected by shotgun proteomics, were validated using targeted proteomics of uEVs obtained from 49 patients with and 48 individuals without bladder cancer, including patients with non-malignant haematuria.
2021-09-20
Relationship between obstetric history and recurrent urinary infections
Urinary tract infections affect more than 50% of woman. 25% derive from recurrent UTI(RUTI).It is known the relationship between obstetric history and RUTI occurrence.